Ki Jun Lee

Mr. Ki Jun Lee

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SHSamantha Hurwitz
Samantha Hurwitz
KLKi Jun Lee
Ki Jun Lee
TFTatiana Fourfouris
Tatiana Fourfouris
ICIrene Choi
Irene Choi
KPKrishan Parikh
Krishan Parikh
YKYong-mi Kim
Yong-mi Kim
The Wnt signaling pathway plays a critical role in regulating normal hematopoiesis and immune cell development. However, its dysregulation has emerged as a key driver of leukemogenesis. Leukemic stem cells exploit aberrant Wnt signaling to sustain self-renewal, evade apoptosis, and promote unchecked proliferation. In this review, we highlight the dual roles of canonical and non-canonical Wnt pathways in acute leukemia, emphasizing their distinct and overlapping contributions to disease progression. We also evaluate current preclinical and clinical strategies targeting Wnt signaling, identifying both promising advances and persistent obstacles to therapeutic translation. By elucidating the molecular mechanisms underlying Wnt pathway dysregulation in leukemic cells, this review underscores the potential of Wnt-directed therapies as a novel class of interventions to improve outcomes for patients with acute leukemia.

23 June 2026 in Experimental Hematology
Verified
Journal Article
Closed access
HKHye Na Kim
Hye Na Kim
SHSamantha Hurwitz
Samantha Hurwitz
TFTatiana Fourfouris
Tatiana Fourfouris
KLKi Jun Lee
Ki Jun Lee
JLJustin Le
Justin Le
YKYong-mi Kim
Yong-mi Kim

5 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ENEbubechukwu Nwarunma
Ebubechukwu Nwarunma
KMKaterina E. Miari
Katerina E. Miari
APAthanasia Papadopoulou
Athanasia Papadopoulou
SCStefan Corradini
Stefan Corradini
GWGlen Watt
Glen Watt
Mark WilliamsMark Williams
Mark Williams
Chemoresistance is a major contributor to poor clinical outcomes in AML patients and can arise from interactions between AML cells and the bone marrow microenvironment (BME). How immune cells, particularly macrophages (Mφs), facilitate this process requires better clarification. This study shows that M2-like Mφs protect AML cells from apoptosis induced by daunorubicin (DNR) and cytarabine (Ara-C). This protection occurs via co-culture and is linked to enhanced mitochondrial transfer from Mφs to AML cells. Mφs interacted with AML cells via tunneling nanotube (TNT)-like structures. Furthermore, inhibition of mitochondrial transfer using cytochalasin B reduced the protective effect, indicating that mitochondria mediate this process. Mφs transferred functional mitochondria to AML cells as evidenced by enhanced metabolic capacity and reduced reactive oxygen species levels in AML cells under chemotherapy stress. TH-257 (LIMK inhibitor) and metformin blocked mitochondrial transfer and Mφ-driven chemoprotection. Moreover, increased transcript expression levels of RhoC and cofilin correlate with inferior overall survival in AML patients. These findings suggest that M2-like Mφs contribute to chemoresistance through TNT-mediated mitochondrial transfer and the LIMK-Cofilin pathway, identifying potential therapeutic targets to circumvent chemoresistance in AML.